Medroxyprogesterone acetate
| MPA | |
|---|---|
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 386.50 g/mol [1] |
| Melting point | 405 to 408 °F (NTP, 1992) [1] |
| Solubility | less than 1 mg/mL at 73 °F (NTP, 1992) [1] |
| Predicted LogP | 4.1 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C24H34O4 |
| IUPAC name | [(6S,8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate |
| SMILES | C[C@H]1C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C |
| InChI | InChI=1S/C24H34O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h13-14,18-20H,6-12H2,1-5H3/t14-,18+,19-,20-,22+,23-,24-/m0/s1 |
| InChIKey | PSGAAPLEWMOORI-PEINSRQWSA-N |
| CAS number | 71-58-9 |
| UNII | C2QI4IOI2G |
| PubChem CID | 6279 |
| Pharmacokinetics[] | |
|---|---|
| Elimination half-life | By mouth: 12–33 hours, Intramuscular injection (aqueous suspension): ~50 days, Subcutaneous injection (aqueous suspension): ~40 days[3][4][5] |
| Metabolism | Liver (hydroxylation (CYP3A4), reduction, conjugation) |
| Excretion | Urine (as conjugates) |
| Routes of administration | By mouth, sublingual, intramuscular injection, subcutaneous injection |
Medroxyprogesterone acetate (also known as Medroxyprogesterone 17-acetate, Provera, Depo-Provera, Metigestrona, Farlutin, Clinovir, Gestapuran, Lutopolar, Perlutex or Oragest) is a hormone and steroid substance of the steroid class.
Chemistry
Stereochemistry []
Medroxyprogesterone acetate is a single defined stereoisomer.
Druglikeness
Lipinski's rule of five
Medroxyprogesterone acetate matches Lipinski's rule of five.Reagents
There are currently 10 reagent-interactions on DrugsPRO
| Reagent | Color change | Description |
|---|---|---|
| Marquis | dark brown | |
| Mecke | dark brown > black | |
| Mandelin | reddish brown | |
| Liebermann | turquoise blue | |
| Froehde | light brown | |
| Robadope | no pink color change | |
| Simon's | deep blue | |
| Ehrlich | no color change | |
| Hofmann | no color change | |
| Gallic | light brown |
Pharmacology
ATC Classification
MeSH Classification
- contraceptive agents, female (M0005103)
- contraceptive agents, male (M0005104)
- contraceptive agents, hormonal (M000646318)
- antineoplastic agents, hormonal (M0028300)
Mechanism of action []
Medroxyprogesterone acetate (MPA) inhibits the production of gonadotropin, preventing follicular maturation and ovulation, which is responsible for it’s ability to prevent pregnancy. This action also thins the endometrium. MPA reduces nuclear estrogen receptors and DNA synthesis in epithelial cells of the endometrium. MPA can also induce p53 dependant apoptosis in certain cancer cell lines, and inhibit GABA-A receptors. [1]
Interactions []
Legal status []
- Australia: Medroxyprogesterone acetate is a Schedule 4.
- Canada: Medroxyprogesterone acetate is Prescription only.[6]
- United States: Medroxyprogesterone acetate is Prescription only.
- Other: Medroxyprogesterone acetate is a Rx-only.
See also []
External links []
- Medroxyprogesterone acetate (Wikipedia)
- Medroxyprogesterone acetate (PubChem)
- Medroxyprogesterone acetate (Wikidata)
- Medroxyprogesterone acetate (DrugBank)
- Medroxyprogesterone acetate (ChEMBL)
- Medroxyprogesterone acetate (ChEBI)
- Medroxyprogesterone acetate (Common Chemistry)
- Medroxyprogesterone acetate (KEGG)
- Medroxyprogesterone acetate (EPA DSSTox)
- Medroxyprogesterone acetate (Effect Index)
- Medroxyprogesterone acetate (UNII)
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 6279, Medroxyprogesterone acetate. Accessed November 21, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/6279
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Medroxyprogesterone acetate. UNII: C2QI4IOI2G. Global Substance Registration System. Accessed November 21, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/C2QI4IOI2G
Provera. FDA. 2015. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/011839s079s080lbl.pdf
Depo_Provera. FDA. 2016. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020246s058lbl.pdf
depo-subQ Provera. FDA. 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021583s023lbl.pdf
Product monograph brand safety updates. Health Canada. February 2024. https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database/label-safety-assessment-update/product-monograph-brand-safety-updates.html
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 13:57:49 |
| drugspro | ok | 2026-11-20 13:57:45 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 13:57:45 |
| gsrs | ok | 2026-11-20 13:57:45 |
| hmdb | missing (no HMDB id) | 2026-11-20 13:57:45 |
| kegg | ok | 2026-11-20 13:57:47 |
| pubchem | ok | 2026-11-20 13:57:44 |
| missing (no r/tripreports posts mention it) | 2026-11-20 13:57:45 | |
| sider | missing (not in SIDER) | 2026-11-20 13:57:45 |
| structure | ok | 2026-11-20 13:57:45 |
| wikipedia | ok | 2026-11-20 13:57:45 |